– USA, FL – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Bill Burke to its Board of Directors, effective July 11, 2022.
“Bill is an excellent addition to our board and brings a depth of finance, business development, and investor relations experience. He has a long history of successful execution helping to bring forward medical solutions that improve patient outcomes and quality of life, which is fully aligned with the Axogen mission,” said CEO, Karen Zaderej.
Bill Burke will also join the Audit Committee as Chair.
About Bill Burke
Mr. Burke is a recognized finance leader in the medical technology industry with more than 25 years of experience in senior leadership positions, including at Haemonetics, Medtronic, and Covidien.
Burke was EVP and CFO of Haemonetics Corporation from August 2016 to June 2022 with responsibility for the global finance organization including investor relations. From July 2014 to July 2016, Burke served as chief integration officer and VP, Integration for Medtronic plc, and was a member of its executive committee. In that role, he was responsible for ensuring the successful integration of Medtronic with Covidien plc following its acquisition by Medtronic. Before joining Medtronic, Burke spent more than 20 years in finance and business development leadership roles at Covidien, including CFO for Covidien Europe based in Zurich, VP of Corporate Strategy and Portfolio Management, and VP of Financial Planning and Analysis. He also previously held key positions within Tyco Healthcare, including the financial controller of Valleylab, managing director of the Covidien Group in Switzerland, and international controller. He began his career as an auditor with KPMG. He currently serves on the board of directors of MiroMatrix (NASDAQ CM: MIRO).
“I am honored to join the Axogen Board of Directors and contribute to the company’s mission of returning nerve function and quality of life to patients with peripheral nerve injuries,” said Bill Burke. “Oxygen is leading the nerve repair industry with an innovative and comprehensive suite of surgical solutions. The potential to help even more nerve repair patients is exciting and I look forward to being a part of it.”
He received his Bachelor of Science degree in Business Administration from Bryant College.
About Axogen
Axogen is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
Axogen’s platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector, a porcine submucosa ECM coaptation aid for the tensionless repair of severed peripheral nerves; Axoguard Nerve Protector, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; and Axoguard Nerve Cap, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of a symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
For more information: https://www.axogeninc.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.